The role of inflammatory mediators in the pathogenesis of Alzheimer’s disease

Sultan Qaboos University Medical Journal

Volumn 15, Issue 3, 2015, Pages e305-e316

  Azizi, Gholamreza ^a,b   Navabi, Shadi S ^b   Al Shukaili, Ahmed ^c   Seyedzadeh, Mir H ^b   Yazdani, Reza ^b,d   Mirshafiey, Abbas ^b  

^a ALBORZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c THE RESEARCH COUNCIL   (Oman)

^d ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acute phase proteins; Alzheimer s disease; Chemokines; Complement system proteins; Cytokines; Inflammation mediators

Indexed keywords

EID: 84940029045     PISSN: 2075051X     EISSN: 20750528     Source Type: Journal    
DOI: 10.18295/squmj.2015.15.03.002     Document Type: Review

References (117)

1. Alzheimer's Association. 2012 Alzheimer's disease facts and figures. Alzheimers Dement 2012; 8:131-68. doi: 10.1016/j. jalz.2012.02.001.
2. Oda H, Yamamoto Y, Maeda K. The neuropsychological profile in dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry 2009; 24:125-31. doi: 10.1002/gps.2078.
3. Alzheimer's Disease International. World Alzheimer report 2014: Dementia and risk reduction - An analysis of protective and modifiable factors. From: www.alz.co.uk/research/ WorldAlzheimerReport2014.pdf Accessed: Feb 2015.
4. Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer's disease: Occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 2009; 11:111-28.
5. Gorlovoy P, Larionov S, Pham TT, Neumann H. Accumulation of tau induced in neurites by microglial proinflammatory mediators. FASEB J 2009; 23:2502-13. doi: 10.1096/fj.08- 123877.
6. Azizi G, Mirshafiey A. The potential role of proinflammatory and antiinflammatory cytokines in Alzheimer disease pathogenesis. Immunopharmacol Immunotoxicol 2012; 34:881-95. doi: 10.3109/08923973.2012.705292.
7. Mirshafiey A, Asghari B, Ghalamfarsa G, Jadidi-Niaragh F, Azizi G. The significance of matrix metalloproteinases in the immunopathogenesis and treatment of multiple sclerosis. Sultan Qaboos Univ Med J 2014; 14:e13-25.
8. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol 2011; 7:137-52. doi: 10.1038/ nrneurol.2011.2.
9. Tuppo EE, Arias HR. The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 2005; 37:289-305. doi: 10. 1016/j.biocel.2004.07.009.
10. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011; 1:a006189. doi: 10.1101/ cshperspect.a006189.
11. Jellinger KA, Bancher C. Neuropathology of Alzheimer's disease: A critical update. J Neural Transm Suppl 1998; 54:77-95. doi: 10.1007/978-3-7091-7508-8_8.
12. McGeer PL, McGeer EG. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: Implications for therapy. Acta Neuropathol 2013; 126:479-97. doi: 10.1007/s00401-013-1177-7.
13. Orsini F, De Blasio D, Zangari R, Zanier ER, De Simoni MG. Versatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis. Front Cell Neurosci 2014; 8:380. doi: 10.3389/fncel.2014.00380.
14. Blach-Olszewska Z, Leszek J. Mechanisms of over-activated innate immune system regulation in autoimmune and neurodegenerative disorders. Neuropsychiatr Dis Treat 2007; 3:365-72.
15. Azizi G, Khannazer N, Mirshafiey A. The potential role of chemokines in Alzheimer's disease pathogenesis. Am J Alzheimers Dis Other Demen 2014: 29:415-25. doi: 10.1177/1533317513518651.
16. Bromley SK, Peterson DA, Gunn MD, Dustin ML. Cutting edge: Hierarchy of chemokine receptor and TCR signals regulating T cell migration and proliferation. J Immunol 2000; 165:15-19. doi: 10.4049/jimmunol.165.1.15.
17. Heneka MT, O'Banion MK, Terwel D, Kummer MP. Neuroinflammatory processes in Alzheimer's disease. J Neural Transm 2010; 117:919-47. doi: 10.1007/s00702-010-0438-z.
18. Rubio-Perez JM, Morillas-Ruiz JM. A review: Inflammatory process in Alzheimer's disease, role of cytokines. ScientificWorldJournal 2012; 2012:756357. doi: 10.1100/2012/756357.
19. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21:383-421. doi: 10.1016/S0197-4580(00)00124-X.
20. Zotova E, Nicoll JA, Kalaria R, Holmes C, Boche D. Inflammation in Alzheimer's disease: Relevance to pathogenesis and therapy. Alzheimers Res Ther 2010; 2:1. doi: 10.1186/alzrt24.
21. Brown GC, Neher JJ. Microglial phagocytosis of live neurons. Nat Rev Neurosci 2014; 15:209-16. doi: 10.1038/nrn3710.
22. Li XQ, Wang J, Fang B, Tan WF, Ma H. Intrathecal antagonism of microglial TLR4 reduces inflammatory damage to bloodspinal cord barrier following ischemia/reperfusion injury in rats. Mol Brain 2014; 7:28. doi: 10.1186/1756-6606-7-28.
23. Lee HG, Won SM, Gwag BJ, Lee YB. Microglial P2X7 receptor expression is accompanied by neuronal damage in the cerebral cortex of the APPswe/PS1dE9 mouse model of Alzheimer's disease. Exp Mol Med 2011; 43:7-14. doi: 10.3858/ emm.2011.43.1.001.
24. Ho GJ, Drego R, Hakimian E, Masliah E. Mechanisms of cell signaling and inflammation in Alzheimer's disease. Curr Drug Targets Inflamm Allergy 2005; 4:247-56. doi: 10.2174/1568010053586237.
25. Fulop T, Lacombe G, Cunnane S, Le Page A, Dupuis G, Frost EH, et al. Elusive Alzheimer's disease: Can immune signatures help our understanding of this challenging disease? Part 2: New immune paradigm. Discov Med 2013; 15:33-42.
26. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010; 362:329-44. doi: 10.1056/NEJMra0909142.
27. Richartz-Salzburger E, Batra A, Stransky E, Laske C, Kohler N, Bartels M, et al. Altered lymphocyte distribution in Alzheimer's disease. J Psychiatr Res 2007; 41:174-8. doi: 10.1016/j. jpsychires.2006.01.010.
28. Skias D, Bania M, Reder AT, Luchins D, Antel JP. Senile dementia of Alzheimer's type (SDAT): Reduced T8+-cellmediated suppressor activity. Neurology 1985; 35:1635-8. doi: 10.1212/WNL.35.11.1635.
29. Giubilei F, Antonini G, Montesperelli C, Sepe-Monti M, Cannoni S, Pichi A, et al. T cell response to amyloid-beta and to mitochondrial antigens in Alzheimer's disease. Dement Geriatr Cogn Disord 2003; 16:35-8. doi: 10.1159/000069991.
30. Panossian LA, Porter VR, Valenzuela HF, Zhu X, Reback E, Masterman D, et al. Telomere shortening in T cells correlates with Alzheimer's disease status. Neurobiol Aging 2003; 24:77-84. doi: 10.1016/S0197-4580(02)00043-X.
31. Zhang J, Kong Q, Zhang Z, Ge P, Ba D, He W. Telomere dysfunction of lymphocytes in patients with Alzheimer disease. Cogn Behav Neurol 2003,16:170-6. doi: 10.1097/00146965- 200309000-00004.
32. Pierson E, Simmons SB, Castelli L, Goverman JM. Mechanisms regulating regional localization of inflammation during CNS autoimmunity. Immunol Rev 2012; 248:205-15. doi: 10.1111/j.1600-065X.2012.01126.x.
33. Monsonego A, Nemirovsky A, Harpaz I. CD4 T cells in immunity and immunotherapy of Alzheimer's disease. Immunology 2013; 139:438-46. doi: 10.1111/imm.12103.
34. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 2005; 25:629-36. doi: 10.1523/JNEUROSCI.4337-04.2005.
35. Galimberti D, Scarpini E. Inflammation and oxidative damage in Alzheimer's disease: Friend or foe? Front Biosci (Schol Ed) 2011; 3:252-66. doi: 10.2741/s149.
36. Sokolova A, Hill MD, Rahimi F, Warden LA, Halliday GM, Shepherd CE. Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain Pathol 2009; 19:392-8. doi: 10.1111/j.1750-3639.2008.00188.x.
37. Belkhelfa M, Rafa H, Medjeber O, Arroul-Lammali A, Behairi N, Abada-Bendib M, et al. IFN-γ and TNF-α are involved during Alzheimer disease progression and correlate with nitric oxide production: A study in Algerian patients. J Interferon Cytokine Res 2014; 34:839-47. doi: 10.1089/ jir.2013.0085.
38. Lin X, Bai G, Lin L, Wu H, Cai J, Ugen KE, et al. Vaccination induced changes in pro-inflammatory cytokine levels as an early putative biomarker for cognitive improvement in a transgenic mouse model for Alzheimer disease. Hum Vaccin Immunother 2014; 10:2024-31. doi: 10.4161/hv.28735.
39. Chakrabarty P, Jansen-West K, Beccard A, Ceballos-Diaz C, Levites Y, Verbeeck C, et al. Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: Evidence against inflammation as a driving force for amyloid deposition. FASEB J 2010; 24:548-59. doi: 10.1096/fj.09-141754.
40. Yu JT, Tan L, Song JH, Sun YP, Chen W, Miao D, et al. Interleukin-18 promoter polymorphisms and risk of late onset Alzheimer's disease. Brain Res 2009; 1253:169-75. doi: 10.1016/j.brainres.2008.11.083.
41. Felderhoff-Mueser U, Schmidt OI, Oberholzer A, Bührer C, Stahel PF. IL-18: A key player in neuroinflammation and neurodegeneration? Trends Neurosci 2005; 28:487-93. doi: 10.1016/j.tins.2005.06.008.
42. Reale M, Kamal MA, Velluto L, Gambi D, Di Nicola M, Greig NH. Relationship between inflammatory mediators, Aβ levels and ApoE genotype in Alzheimer disease. Curr Alzheimer Res 2012; 9:447-57. doi: 10.2174/156720512800492549.
43. Conti B, Park LC, Calingasan NY, Kim Y, Kim H, Bae Y, et al. Cultures of astrocytes and microglia express interleukin 18. Brain Res Mol Brain Res 1999; 67:46-52. doi: 10.1016/S0169- 328X(99)00034-0.
44. Kawanokuchi J, Mizuno T, Takeuchi H, Kato H, Wang J, Mitsuma N, et al. Production of interferon-gamma by microglia. Mult Scler 2006; 12:558-64. doi: 10.1177/1352458506070763.
45. Schmitt TL, Steiner E, Klinger P, Sztankay A, Grubeck- Loebenstein B. The production of an amyloidogenic metabolite of the Alzheimer amyloid beta precursor protein (APP) in thyroid cells is stimulated by interleukin 1 beta, but inhibited by interferon gamma. J Clin Endocrinol Metab 1996; 81:1666-9. doi: 10.1210/jcem.81.4.8636387.
46. Noguchi A, Nawa M, Aiso S, Okamoto K, Matsuoka M. Transforming growth factor beta2 level is elevated in neurons of Alzheimer's disease brains. Int J Neurosci 2010; 120:168-75. doi: 10.3109/00207450903139689.
47. Eslami P, Johnson MF, Terzakaryan E, Chew C, Harris-White ME. TGF beta2-induced changes in LRP-1/T beta R-V and the impact on lysosomal A beta uptake and neurotoxicity. Brain Res 2008; 1241:176-87. doi: 10.1016/j.brainres.2008.08.086.
48. Caraci F, Spampinato S, Sortino MA, Bosco P, Battaglia G, Bruno V, et al. Dysfunction of TGF-beta1 signaling in Alzheimer's disease: Perspectives for neuroprotection. Cell Tissue Res 2012; 347:291-301. doi: 10.1007/s00441-011-1230-6.
49. Hickman SE, El Khoury J. Mechanisms of mononuclear phagocyte recruitment in Alzheimer's disease. CNS Neurol Disord Drug Targets 2010; 9:168-73. doi: 10.2174/ 187152710791011982.
50. D'Mello C, Le T, Swain MG. Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factor alpha signaling during peripheral organ inflammation. J Neurosci 2009; 29:2089-102. doi: 10.1523/JNEUROSCI.3567-08.2009.
51. Selenica ML, Alvarez JA, Nash KR, Lee DC, Cao C, Lin X, et al. Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain. J Neuroinflammation 2013; 10:86. doi: 10.1186/1742-2094-10-86.
52. Tripathy D, Thirumangalakudi L, Grammas P. RANTES upregulation in the Alzheimer's disease brain: A possible neuroprotective role. Neurobiol Aging 2010; 31:8-16. doi: 10.1016/j.neurobiolaging.2008.03.009.
53. Sharma V, Mishra M, Ghosh S, Tewari R, Basu A, Seth P, et al. Modulation of interleukin-1beta mediated inflammatory response in human astrocytes by flavonoids: Implications in neuroprotection. Brain Res Bull 2007; 73:55-63. doi: 10.1016/j. brainresbull.2007.01.016.
54. Lumpkins K, Bochicchio GV, Zagol B, Ulloa K, Simard JM, Schaub S, et al. Plasma levels of the beta chemokine regulated upon activation, normal T cell expressed, and secreted (RANTES) correlate with severe brain injury. J Trauma 2008; 64:358-61. doi: 10.1097/TA.0b013e318160df9b.
55. Vago L, Nebuloni M, Bonetto S, Pellegrinelli A, Zerbi P, Ferri A, et al. Rantes distribution and cellular localization in the brain of HIV-infected patients. Clin Neuropathol 2001; 20:139-45.
56. Laske C, Stellos K, Eschweiler GW, Leyhe T, Gawaz M. Decreased CXCL12 (SDF-1) plasma levels in early Alzheimer's disease: A contribution to a deficient hematopoietic brain support? J Alzheimers Dis 2008; 15:83-95.
57. Li M, Hale JS, Rich JN, Ransohoff RM, Lathia JD. Chemokine CXCL12 in neurodegenerative diseases: An SOS signal for stem cell-based repair. Trends Neurosci 2012; 35:619-28. doi: 10.1016/j.tins.2012.06.003.
58. Zhu B, Xu D, Deng X, Chen Q, Huang Y, Peng H, et al. CXCL12 enhances human neural progenitor cell survival through a CXCR7- and CXCR4-mediated endocytotic signaling pathway. Stem Cells 2012; 30:2571-83. doi: 10.1002/stem.1239.
59. Raman D, Milatovic SZ, Milatovic D, Splittgerber R, Fan GH, Richmond A. Chemokines, macrophage inflammatory protein-2 and stromal cell-derived factor-1α, suppress amyloid β-induced neurotoxicity. Toxicol Appl Pharmacol 2011; 256:300-13. doi: 10.1016/j.taap.2011.06.006.
60. Kim TS, Lim HK, Lee JY, Kim DJ, Park S, Lee C, et al. Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett 2008; 436:196-200. doi: 10.1016/j.neulet.2008.03.019.
61. Cho SH, Sun B, Zhou Y, Kauppinen TM, Halabisky B, Wes P, et al. CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J Biol Chem 2011; 286:32713-22. doi: 10.1074/jbc.M111.254268.
62. Popp J, Bacher M, Kölsch H, Noelker C, Deuster O, Dodel R, et al. Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease. J Psychiatr Res 2009; 43:749-53. doi: 10.1016/j.jpsychires.2008.10.006.
63. Al-Abed Y, VanPatten S. MIF as a disease target: ISO-1 as a proof-of-concept therapeutic. Future Med Chem 2011; 3: 45-63. doi: 10.4155/fmc.10.281.
64. Bacher M, Deuster O, Aljabari B, Egensperger R, Neff F, Jessen F, et al. The role of macrophage migration inhibitory factor in Alzheimer's disease. Mol Med 2010; 16:116-21. doi: 10.2119/molmed.2009.00123.
65. Oyama R, Yamamoto H, Titani K. Glutamine synthetase, hemoglobin alpha-chain, and macrophage migration inhibitory factor binding to amyloid beta-protein: Their identification in rat brain by a novel affinity chromatography and in Alzheimer's disease brain by immunoprecipitation. Biochim Biophys Acta 2000; 1479:91-102. doi: 10.1016/S0167-4838(00)00057-1.
66. Lashuel HA, Aljabari B, Sigurdsson EM, Metz CN, Leng L, Callaway DJ, et al. Amyloid fibril formation by macrophage migration inhibitory factor. Biochem Biophys Res Commun 2005; 338:973-80. doi: 10.1016/j.bbrc.2005.10.040.
67. Xia MQ, Qin SX, Wu LJ, Mackay CR, Hyman BT. Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. Am J Pathol 1998; 153:31-7.
68. Man SM, Ma YR, Shang DS, Zhao WD, Li B, Guo DW, et al. Peripheral T cells overexpress MIP-1alpha to enhance its transendothelial migration in Alzheimer's disease. Neurobiol Aging 2007; 28:485-96. doi: 10.1016/j. neurobiolaging.2006.02.013.
69. Li K, Dai D, Yao L, Gu X, Luan K, Tian W, et al. Association between the macrophage inflammatory protein-l alpha gene polymorphism and Alzheimer's disease in the Chinese population. Neurosci Lett 2008; 433:125-8. doi: 10.1016/j. neulet.2008.01.002.
70. Passos GF, Figueiredo CP, Prediger RD, Pandolfo P, Duarte FS, Medeiros R, et al. Role of the macrophage inflammatory protein-1alpha/CC chemokine receptor 5 signaling pathway in the neuroinflammatory response and cognitive deficits induced by beta-amyloid peptide. Am J Pathol 2009; 175:1586-97. doi: 10.2353/ajpath.2009.081113.
71. Kolev MV, Ruseva MM, Harris CL, Morgan BP, Donev RM. Implication of complement system and its regulators in Alzheimer's disease. Curr Neuropharmacol 2009; 7:1-8. doi: 10.2174/157015909787602805.
72. Shen Y, Yang L, Li R. What does complement do in Alzheimer's disease? Old molecules with new insights. Transl Neurodegener 2013; 2:21. doi: 10.1186/2047-9158-2-21.
73. Fraser DA, Pisalyaput K, Tenner AJ. C1q enhances microglial clearance of apoptotic neurons and neuronal blebs, and modulates subsequent inflammatory cytokine production. J Neurochem 2010; 112:733-43. doi: 10.1111/j.1471-4159.2009.06494.x.
74. Alexander JJ, Anderson AJ, Barnum SR, Stevens B, Tenner AJ. The complement cascade: Yin-Yang in neuroinflammationneuro- protection and -degeneration. J Neurochem 2008; 107:1169-87. doi: 10.1111/j.1471-4159.2008.05668.x.
75. Benoit ME, Hernandez MX, Dinh ML, Benavente F, Vasquez O, Tenner AJ. C1q-induced LRP1B and GPR6 proteins expressed early in Alzheimer disease mouse models, are essential for the C1q-mediated protection against amyloid-beta neurotoxicity. J Biol Chem 2013; 288:654-65. doi: 10.1074/jbc.M112.400168.
76. Benoit ME, Tenner AJ. Complement protein C1q-mediated neuroprotection is correlated with regulation of neuronal gene and microRNA expression. J Neurosci 2011; 31:3459-69. doi: 10.1523/JNEUROSCI.3932-10.2011.
77. Loeffler DA, Camp DM, Bennett DA. Plaque complement activation and cognitive loss in Alzheimer's disease. J Neuroinflammation 2008; 5:9. doi: 10.1186/1742-2094-5-9.
78. Eikelenboom P, Hoozemans JJ, Veerhuis R, van Exel E, Rozemuller AJ, van Gool WA. Whether, when and how chronic inflammation increases the risk of developing lateonset Alzheimer's disease. Alzheimers Res Ther 2012; 4:15. doi: 10.1186/alzrt118.
79. Kravitz BA, Corrada MM, Kawas CH. Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-old. Alzheimers Dement 2009; 5:318-23. doi: 10.1016/j. jalz.2009.04.1230.
80. Komulainen P, Lakka TA, Kivipelto M, Hassinen M, Penttilä IM, Helkala EL, et al. Serum high sensitivity C-reactive protein and cognitive function in elderly women. Age Ageing 2007; 36:443-8. doi: 10.1093/ageing/afm051.
81. Strang F, Scheichl A, Chen YC, Wang X, Htun NM, Bassler N, et al. Amyloid plaques dissociate pentameric to monomeric C-reactive protein: A novel pathomechanism driving cortical inflammation in Alzheimer's disease? Brain Pathol 2012; 22:337-46. doi: 10.1111/j.1750-3639.2011.00539.x.
82. Helmy AA, Naseer MM, Shafie SE, Nada MA. Role of interleukin 6 and alpha-globulins in differentiating Alzheimer and vascular dementias. Neurodegener Dis 2012; 9:81-6. doi: 10.1159/000329568.
83. O'Bryant SE, Waring SC, Hobson V, Hall JR, Moore CB, Bottiglieri T, et al. Decreased C-reactive protein levels in Alzheimer disease. J Geriatr Psychiatry Neurol 2010; 23:49-53. doi: 10.1177/0891988709351832.
84. Sundelöf J, Kilander L, Helmersson J, Larsson A, Rönnemaa E, Degerman-Gunnarsson M, et al. Systemic inflammation and the risk of Alzheimer's disease and dementia: A prospective population-based study. J Alzheimers Dis 2009; 18:79-87. doi: 10.3233/JAD-2009-1126.
85. Mohsenzadegan M, Mirshafiey A. The immunopathogenic role of reactive oxygen species in Alzheimer disease. Iran J Allergy Asthma Immunol 2012; 11:203-16. doi: 011.03/ijaai.203216.
86. Shen S, Callaghan D, Juzwik C, Xiong H, Huang P, Zhang W. ABCG2 reduces ROS-mediated toxicity and inflammation: a potential role in Alzheimer's disease. J Neurochem 2010; 114:1590-1604. doi: 10.1111/j.1471-4159.2010.06887.x.
87. Xiong H, Callaghan D, Jones A, Bai J, Rasquinha I, Smith C, et al. ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the bloodbrain barrier for Abeta(1-40) peptides. J Neurosci 2009; 29:5463-75. doi: 10.1523/JNEUROSCI.5103-08.2009.
88. Vladimirova O, Lu FM, Shawver L, Kalman B. The activation of protein kinase C induces higher production of reactive oxygen species by mononuclear cells in patients with multiple sclerosis than in controls. Inflamm Res 1999; 48:412-16. doi: 10.1007/ s000110050480.
89. Aliev G, Priyadarshini M, Reddy VP, Grieg NH, Kaminsky Y, Cacabelos R, et al. Oxidative stress mediated mitochondrial and vascular lesions as markers in the pathogenesis of Alzheimer disease. Curr Med Chem 2014; 21:2208-17. doi: 10.2174/09298 67321666131227161303.
90. Cornelius C, Koverech G, Crupi R, Di Paola R, Koverech A, Lodato F, et al. Osteoporosis and Alzheimer pathology: Role of cellular stress response and hormetic redox signaling in aging and bone remodeling. Front Pharmacol 2014; 5:120. doi: 10.3389/fphar.2014.00120.
91. Sarti P, Arese M, Giuffre A. The molecular mechanisms by which nitric oxide controls mitochondrial complex IV. Ital J Biochem 2003; 52:37-42.
92. Sheng B, Gong K, Niu Y, Liu L, Yan Y, Lu G, et al. Inhibition of gamma-secretase activity reduces Abeta production, reduces oxidative stress, increases mitochondrial activity and leads to reduced vulnerability to apoptosis: Implications for the treatment of Alzheimer's disease. Free Radic Biol Med 2009; 46:1362-75. doi: 10.1016/j.freeradbiomed.2009.02.018.
93. Bodovitz S, Klein WL. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 1996; 271:4436-40.
94. Mirshafiey A, Mohsenzadegan M. The role of reactive oxygen species in immunopathogenesis of rheumatoid arthritis. Iran J Allergy Asthma Immunol 2008; 7:195-202. doi: 07.04/ ijaai.195202.
95. Ferretti MT, Bruno MA, Ducatenzeiler A, Klein WL, Cuello AC. Intracellular Aβ-oligomers and early inflammation in a model of Alzheimer's disease. Neurobiol Aging 2012; 33:1329-42. doi: 10.1016/j.neurobiolaging.2011.01.007.
96. Ferrera P, Arias C. Differential effects of COX inhibitors against beta-amyloid-induced neurotoxicity in human neuroblastoma cells. Neurochem Int 2005; 47:589-96. doi: 10.1016/j.neuint.200 5.06.012.
97. Lee M, Sparatore A, Del Soldato P, McGeer E, McGeer PL. Hydrogen sulfide-releasing NSAIDs attenuate neuroinflammation induced by microglial and astrocytic activation. Glia 2010; 58:103-13. doi: 10.1002/glia.20905.
98. Shi J, Wang Q, Johansson JU, Liang X, Woodling NS, Priyam P, et al. Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease. Ann Neurol 2012; 72:788-98. doi: 10.1002/ana.23677.
99. Alzheimer's Association. FDA-Approved treatments for Alzheimer's. From: www.alz.org/national/documents/topicsheet_ treatments.pdf Accessed: Feb 2015.
100. Zemek F, Drtinova L, Nepovimova E, Sepsova V, Korabecny J, Klimes J, et al. Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine. Expert Opin Drug Saf 2014; 13:759-74. doi: 10.1517/14740338.2014.914168.
101. Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease: A brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2012; 2:a006346. doi: 10.1101/ cshperspect.a006346.
102. McNaull BB, Todd S, McGuinness B, Passmore AP. Inflammation and anti-inflammatory strategies for Alzheimer's disease: A mini-review. Gerontology 2010; 56:3-14. doi: 10.1 159/000237873.
103. Yu D, Corbett B, Yan Y, Zhang GX, Reinhart P, Cho SJ, et al. Early cerebrovascular inflammation in a transgenic mouse model of Alzheimer's disease. Neurobiol Aging 2012; 33:2942-7. doi: 10.1016/j.neurobiolaging.2012.02.023.
104. Leoutsakos JM, Muthen BO, Breitner JC, Lyketsos CG; ADAPT Research Team. Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of preclinical Alzheimer disease: Findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial. Int J Geriatr Psychiatry 2012; 27:364-74. doi: 10.1002/ gps.2723.
105. Jaturapatporn D, Isaac MG, McCleery J, Tabet N. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev 2012; 2:CD006378. doi: 10.1002/14651858.CD006378.pub2.
106. Lemere CA. Immunotherapy for Alzheimer's disease: Hoops and hurdles. Mol Neurodegener 2013; 8:36. doi: 10.1186/1750- 1326-8-36.
107. Clinical Trials, USA National Institutes of Health. Progress of mild Alzheimer's disease in participants on solanezumab versus placebo (EXPEDITION 3). From: https://clinicaltrials.gov/ct2/ show/NCT01900665 Accessed: Feb 2015.
108. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367:795-804. doi: 10.1056/NEJMoa1202753.
109. Lambracht-Washington D, Rosenberg RN. Advances in the development of vaccines for Alzheimer's disease. Discov Med 2013; 15:319-26.
110. Qu B, Boyer PJ, Johnston SA, Hynan LS, Rosenberg RN. Abeta42 gene vaccination reduces brain amyloid plaque burden in transgenic mice. J Neurol Sci 2006; 244:151-8.
111. DaSilva KA, Brown ME, McLaurin J. Reduced oligomeric and vascular amyloid-beta following immunization of TgCRND8 mice with an Alzheimer's DNA vaccine. Vaccine 2009; 27:1365-76. doi: 10.1016/j.vaccine.2008.12.044.
112. Ubhi K, Masliah E. Alzheimer's disease: Recent advances and future perspectives. J Alzheimers Dis 2013; 33:S185-94. doi: 10. 3233/JAD-2012-129028.
113. Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A, et al. Extensive involvement of autophagy in Alzheimer disease: An immuno-electron microscopy study. J Neuropathol Exp Neurol 2005; 64:113-22.
114. Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH, et al. Macroautophagy: A novel Beta-amyloid peptidegenerating pathway activated in Alzheimer's disease. J Cell Biol 2005; 171:87-98. doi: 10.1083/jcb.200505082.
115. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and tau: Effects on cognitive impairments. J Biol Chem 2010; 285:13107-20. doi: 10.1074/ jbc.M110.100420.
116. Martorana A, Balistreri CR, Bulati M, Buffa S, Azzarello DM, Camarda C, et al. Double negative (CD19+IgG+IgD-CD27-) B lymphocytes: A new insight from telomerase in healthy elderly, in centenarian offspring and in Alzheimer's disease patients. Immunol Lett 2014; 162:303-9. doi: 10.1016/j. imlet.2014.06.003.
117. Colonna-Romano G, Bulati M, Aquino A, Pellicanò M, Vitello S, Lio D, et al. A double-negative (IgD-CD27-) B cell population is increased in the peripheral blood of elderly people. Mech Ageing Dev 2009; 130:681-90. doi: 10.1016/j. mad.2009.08.003.